Close

AveXis (AVXS) Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1

March 16, 2017 4:10 PM EDT Send to a Friend
AveXis, Inc. (NASDAQ: AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login